Oncolytics Biotech Reports Durability and Survival Data in Anal Cancer
Oncolytics Biotech reported durability and survival data in anal cancer and described pelareorep as a potential backbone immunotherapy across HPV-driven cancers.
Oncolytics Biotech reported durability and survival data in anal cancer and described pelareorep as a potential backbone immunotherapy across HPV-driven cancers.